Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Bradley L. Campbell sold 10,514 shares of the business’s stock in a transaction dated Monday, June 7th. The stock was sold at an average price of $10.01, for a total value of $105,245.14. Following the completion of the sale, the chief operating officer now directly owns 436,397 shares of the company’s stock, valued at approximately $4,368,333.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Bradley L. Campbell also recently made the following trade(s):
- On Monday, May 3rd, Bradley L. Campbell sold 10,514 shares of Amicus Therapeutics stock. The stock was sold at an average price of $10.27, for a total value of $107,978.78.
NASDAQ FOLD opened at $10.71 on Friday. The company has a quick ratio of 4.86, a current ratio of 5.05 and a debt-to-equity ratio of 1.55. The firm’s 50 day moving average is $9.63. The firm has a market capitalization of $2.85 billion, a P/E ratio of -11.04 and a beta of 1.15. Amicus Therapeutics, Inc. has a 1-year low of $8.68 and a 1-year high of $25.39.
FOLD has been the topic of a number of recent analyst reports. Cantor Fitzgerald upgraded Amicus Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Monday, April 19th. Robert W. Baird reiterated a “buy” rating on shares of Amicus Therapeutics in a research note on Wednesday, March 3rd. UBS Group initiated coverage on Amicus Therapeutics in a research note on Thursday, May 20th. They issued a “buy” rating and a $16.00 price objective on the stock. Needham & Company LLC initiated coverage on Amicus Therapeutics in a research note on Thursday, May 27th. They issued a “hold” rating on the stock. Finally, SVB Leerink reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $20.00.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Horizon Advisors Inc. acquired a new stake in Amicus Therapeutics during the first quarter valued at approximately $27,000. Harbor Investment Advisory LLC boosted its holdings in shares of Amicus Therapeutics by 76.6% in the 1st quarter. Harbor Investment Advisory LLC now owns 4,670 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 2,026 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Amicus Therapeutics by 95.5% in the 1st quarter. Lazard Asset Management LLC now owns 5,657 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 2,763 shares in the last quarter. Twin Lakes Capital Management LLC acquired a new position in shares of Amicus Therapeutics in the 1st quarter worth approximately $59,000. Finally, Fieldpoint Private Securities LLC acquired a new position in shares of Amicus Therapeutics in the 1st quarter worth approximately $71,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates.
Featured Article: Why do analysts give a neutral rating?
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.